Bivalirudin
Bivalirudin is a direct thrombin inhibitor given by vein as an anticoagulant. The US label read lists one use: as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI (percutaneous coronary intervention)), including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS). The label says it binds thrombin directly and reversibly.
Also called Angiomax
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 60819; UNII TN9BEX005G. MeSH has no descriptor for bivalirudin (an exact-label lookup and a contains lookup on 2026-11-09 returned none), so no MeSH identifier is recorded. Classes: Direct Thrombin Inhibitor and Anti-coagulant (FDA established pharmacologic classes, RxClass). The label read is the Civica, Inc. label for bivalirudin for injection, application NDA020873 (the application of the brand product Angiomax), effective 2025-09-10 in openFDA. openFDA returned no brand-named Angiomax record. Other bivalirudin labels were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 13 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 13
- Phase 3 or 4
- 13
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 3 | 2 | 1 | 1 | 4 |
| Phase 4 | 5 | 0 | 4 | 9 |
| All phases | 7 | 1 | 5 | 13 |
Conditions these trials study
- Heart attack (myocardial infarction)
- ST-elevation heart attack (STEMI)
- Acute coronary syndrome
- Coronary artery disease
- Aortic stenosis
- Heart valve disease
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- The label says bivalirudin binds thrombin directly, at its catalytic site and its anion-binding exosite, and that the binding is reversible.
Claims and evidence
Context People for whom the US label of bivalirudin for injection lists an indication: anticoagulation during percutaneous coronary intervention, including heparin-induced thrombocytopenia
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label passage read does not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passage read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Patients undergoing percutaneous coronary intervention (PCI (percutaneous coronary intervention))
- Patients undergoing PCI who have heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS)
- Excluded
- None stated
The US label of bivalirudin for injection, in the Civica, Inc. version dated 2025-09-10 in openFDA (application NDA020873), describes bivalirudin as a direct thrombin inhibitor and lists it for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).
Applies to Recipient not specified People for whom the US label of bivalirudin for injection lists an indication: anticoagulation during percutaneous coronary intervention, including heparin-induced thrombocytopenia
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; contraindications, doses, interactions and other warnings were not read. The atlas has no page for heparin-induced thrombocytopenia, so no edge to it is recorded. Labels differ between sponsors and change over time. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE (highlights)
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2025-09-10
- Source state
- Current
- Version fingerprint
f0c2c42a75f215c009acc029d902785ae6f38dd5fac72d6557571d71259a64d8- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250910.
- Retrieved
- Source effective date
- 2025-09-10
- Source state
- Current
- Version fingerprint
f0c2c42a75f215c009acc029d902785ae6f38dd5fac72d6557571d71259a64d8- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
ANGIOMAX
No label from the application holder was found in the openFDA label dataset for application NDA020873. This page does not show another labeler's label in its place.
ANGIOMAX RTU
No label from the application holder was found in the openFDA label dataset for application NDA211215. This page does not show another labeler's label in its place.
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE
No label from the application holder was found in the openFDA label dataset for application NDA208374. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 3
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 13
Record details
- Record id
cardio:bivalirudin- Content hash
cad976b70bd8828393afa360ab43693bca394a20e8f4d19c3984abe34930c1ae